ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Portfolio Pulse from
Atara Biotherapeutics' stock dropped 41% after the FDA issued a Complete Response Letter (CRL) for its blood cancer treatment candidate, Ebvallo. The company is also experiencing significant financial difficulties.
January 17, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atara Biotherapeutics' stock fell 41% following the FDA's issuance of a CRL for its blood cancer treatment candidate, Ebvallo. The company is also dealing with a cash shortage.
The FDA's CRL is a significant setback for Atara's Ebvallo, directly impacting its stock price negatively. The additional financial strain from a cash crunch exacerbates the situation, leading to a sharp decline in investor confidence.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100